1- amino- 6- (3,5- dimethyl- 1- adamantylamine)hexane
a blocker of both NMDA and AMPA receptors; has both anticonvulsant and neuroprotective activities
Also Known As:
1-amino-6-(3,5-dimethyl-1-adamantylamine)hexane dihydrochloride; IEM-2121
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Seizures (Absence Seizure)
05/01/2014
- " The intramuscular injection of novel agent IEM-2121 (0.03-1.00 mg/kg) known to block both AMPA and NMDA receptors, prevented the clonic kainate seizures only in 50-70%, although it precluded the chronic kainate lethality in 100%. " 05/01/2013
- " IEM-2121, causing combined blockade of NMDA- and AMPA-glutamate receptors, as well as IEM-1676, which also blocks AMPA-, NMDA- and N-cholinoreceptors, both after peroral chronic administration in a doses 10 mg/kg and 20 mg/kg accordingly, possess higher, than sodium valproate, anticonvulsant activity because reduce average severity of pentylenetetrazol kindling seizures in 2.4-2.7 times in comparison with control and prevents clonic kindling seizures in 87% of rats. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures